Factor IXa binds emicizumab

Stable Identifier
R-HSA-9678390
Type
Reaction [binding]
Species
Homo sapiens
Compartment
extracellular region, plasma membrane
ReviewStatus
3/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Factor IXa binds emicizumab
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Emicizumab (also known as ACE910, trade name Hemlibra) is a bispecific humanized monoclonal antibody that restores the function of missing activated clotting factor VIII (FVIII) by bridging activated FIX and FX to facilitate effective hemostasis in patients with hemophilia A (HEMA) (Sampei Z et al. 2013; Kitazawa T et al. 2017, 2020). Emicizumab recognizes the epidermal growth factor (EGF)-like domain 1 of FIX/FIXa with one arm and the EGF-like domain 2 of FX/FXa with the other arm (Kitazawa T et al. 2017). The FVIIIa-cofactor activity of emicizumab is thought to depend on phosphatidylserine-exposed phospholipid membrane (Kitazawa T et al. 2017).
Literature References
PubMed ID Title Journal Year
28451690 Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

Kitazawa, T, Esaki, K, Tachibana, T, Ishii, S, Soeda, T, Muto, A, Kawabe, Y, Igawa, T, Tsunoda, H, Nogami, K, Shima, M, Hattori, K

Thromb. Haemost. 2017
30350119 Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity

Kitazawa, T, Shima, M

Int. J. Hematol. 2020
Participants
Input
Output
Participates
as an event of
Disease
Name Identifier Synonyms
factor VIII deficiency DOID:12134 Congenital factor VIII disorder, Subhemophilia, Hemophilia A
Cross References
Mondo
Authored
Shamovsky, V  (2024-11-20)
Created
Shamovsky, V  (2020-03-19)
Cite Us!